Genmab to start Phase III HuMax-CD4 trial

Genmab (CSE:GEN; NMarkt:GE9D) said it will start this month a U.S. and European Phase III trial of HuMax-CD4 human antibody against CD4 receptors on T cells to treat active rheumatoid arthritis. In th...